Syndax (SNDX) Q2 FY26 earnings call

Syndax delivered a quarter of robust commercial performance for its key products, Revuforj and Niktimvo, with both demonstrating strong revenue growth and increasing treatment durations. The company also advanced its pipeline with two new assets and anticipates several key data readouts in the near future. Despite a temporary fluctuation in Revuforj new patient starts, management remains confident in its growth trajectory and financial position to fund ongoing commercial and R&D priorities.